Sell RIM!: Against ...
Cytokinetics Inc. (CYTK: NASDAQ)
$0.88 -0.02 | -2.17%
06/04/12 - 03:59 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| CYTK | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -14.29 | -34.31 | -67.97 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 55.20 | -0.68 | -0.31 |
| Net Income | -0.15 | 0.00 | |
| EPS | -0.37 | 0.00 |
Earnings for CYTK:
| EBITDA | -45.00 |
| REVENUE | 4.00M |
Average Earnings Estimates
| Qtr (06/12) | Qtr (09/12) | FY (12/12) | FY (12/13) | |
|---|---|---|---|---|
| Average Estimate | $-0.14 | $0.00 | $-0.43 | $-0.15 |
| Number of Analysts | 3 | 3 | 4 | 4 |
| High Estimate | $-0.14 | $0.24 | $-0.16 | $0.16 |
| Low Estimate | $-0.15 | $-0.14 | $-0.56 | $-0.51 |
| Prior Year | $-0.23 | $-0.15 | $-0.70 | $-0.43 |
| Growth Rate (Year over Year) | 37.68% | 97.78% | 38.21% | 66.47% |
Portfolios with CYTK
- Portfolio NameUser Type
- Contributor$5 Stocks That Analysts Exp...
- UserBlue OAK
- UserDaveofDuke1111
- UserASCO 2010 Part 2
- ContributorBarron's Insider Purchases ...
- UserASCO 2009 Nymph's Watch List.
- UserHot Biotech Stocks II
- UserLet's Go Channeling
- UserDizziMage's Port
- Usermileslb Fidelity IRA
Latest CYTK Headlines from TheStreet
- Cytokinetics CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 11:10 pm
- $5 Stocks That Analysts Expect to Double 08.02.10 | 06:08 am
- Cytokinetics Inc. Q2 2010 Earnings Call Transcript 07.29.10 | 03:07 am
- Cytokinetics Ends Cancer Deal With GlaxoSmithKline 12.09.09 | 04:12 pm
- Movers Roundup: Manitowoc, Symantec 10.29.09 | 02:10 pm
- Cytokinetics Shares Fall On Drug Development Delay 10.29.09 | 12:10 pm
- Harmonic, SkyPeople: Midday Volume Plays 10.29.09 | 12:10 pm
- High Times
09.29.09 | 10:09 am - Cytokinetics: Pump Up The Volume 09.25.09 | 03:09 pm
- Optimer Soars on Antibiotic Data 11.11.08 | 12:11 pm
Press Releases for CYTK
Partner Headlines for CYTK
- Rodman & Renshaw Reiterates Cytokinetics Market Outperform, $4 PT - Benzinga 11.01.11 | 04:11 pm
- 16 Small Caps With Cash to Cover 1+ Years of Operating Expenses - Seeking Alpha 04.20.11 | 04:04 am
- Cytokinetics Up 9% (CYTK) - Benzinga 04.12.11 | 09:04 am
- Cytokinetics: Most Recent Victim of Unjustified Biotech Sell-Off - Seeking Alpha 12.19.10 | 07:12 am
- UPDATE 1-Cytokinetics' Lou Gehrig's drug gets orphan status - Reuters 03.10.10 | 09:03 am





